Welcome to our dedicated page for CARLSMED news (Ticker: CARL), a resource for investors and traders seeking the latest updates and insights on CARLSMED stock.
Carlsmed, Inc. (Nasdaq: CARL) is a medical technology company that reports on the commercial progress of its AI-enabled personalized spine surgery platform, aprevo. News about Carlsmed often centers on its revenue growth as a commercial-stage company, updates on surgeon adoption of the aprevo platform, and financial guidance shared in quarterly results and preliminary annual revenue announcements.
Investors following CARL news can expect regular earnings releases that discuss revenue, gross profit, operating expenses, net loss, cash and cash equivalents, and non-GAAP measures such as Adjusted EBITDA. These releases are typically accompanied by conference call and webcast details, and they are referenced in the company’s Form 8-K filings with the SEC. Carlsmed also issues news about amendments to its loan and security agreement and related warrant arrangements, which provide insight into its access to debt financing and capital structure.
Beyond financial updates, Carlsmed publishes news on clinical and product milestones for the aprevo Technology Platform. This includes announcements of clinical study publications in journals such as Global Spine Journal, data presented at meetings like the Scoliosis Research Society Annual Meeting, and the U.S. commercial launch of its aprevo Technology Platform for cervical fusion surgeries. The company’s releases highlight findings on revision rates, mechanical complications, and alignment outcomes when using personalized, patient-specific interbody implants and AI-enabled preoperative planning.
Carlsmed also announces participation in major healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference and the Piper Sandler Healthcare Conference, as well as index-related developments like its addition to the Russell 2000 Index. These items provide context on how the market and the medical community engage with the company. For ongoing coverage of CARL, this news page aggregates Carlsmed’s financial disclosures, clinical updates, reimbursement developments, and corporate events in one place.
Carlsmed (NASDAQ:CARL), a commercial-stage medical technology company specializing in AI-enabled personalized spine surgery solutions, has announced its initial public offering. The company plans to offer 6.7 million shares of common stock with an expected price range of $14.00 to $16.00 per share.
The underwriters will have a 30-day option to purchase up to 1,005,000 additional shares. BofA Securities, Goldman Sachs & Co. LLC, and Piper Sandler are serving as joint lead book-running managers, while Truist Securities and BTIG are acting as joint book-runners. The company has applied to list on the Nasdaq Global Select Market under the ticker symbol "CARL".